AIM:To evaluate the efficacy of treating traumatic optic neuropathy(TON)with mouse nerve growth factor.

METHODS: We searched the Cochrane Library, Pubmed, Medline,CNKI, Wanfang database and VIP to collect randomized controlled trials(RCTs)of using mouse nerve growth factor for TON. The quality of the included trials was assessed and poor-qualified trials were eliminated before the meta-analysis was conducted.

RESULTS: Seven RCTs with a total of 399 eyes included were retrieved, and OR=3.78 with a 95%CI of \〖2.35, 6.06\〗, the difference was significant(P<0.01).

CONCLUSION: The existing evidence supports that the prognosis of TON is better when mouse nerve growth factor are adopted in treatment, but there is still a need for well-planned, large-scale and multicenter RCTs to verify it.